Abiopharma

🔍 O'BRIEN DEIRDRE (Executive)

Company: Apple Inc. (AAPL)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 64,317 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 201,127.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 34,315 shares of Common Stock at $255.63 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 166,812.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 20,338 shares of Common Stock at $255.12 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 146,474.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 9,664 shares of Common Stock at $255.82 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 136,810.00 | transaction_form_type: 4 | Footnotes: F4, F6
• Sold 22,688 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F7, F7
• Sold 22,159 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,159.00 | transaction_form_type: 4 | Footnotes: F1, F1, F8, F8
• Sold 19,470 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 38,938.00 | transaction_form_type: 4 | Footnotes: F1, F1, F9, F9

Footnotes:

• F1: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one share of common stock. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
• F2: The number of securities reported reflects the acquisition on January 30, 2026 of 123 shares of Apple Inc.'s common stock pursuant to the Apple Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 1, 2025 through January 30, 2026.
• F3: Shares withheld by Apple to satisfy tax withholding requirements on vesting of RSUs.
• F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2025.
• F5: This transaction was executed in multiple trades at prices ranging from $254.505 to 255.485; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Apple, or a security holder of Apple.
• F6: This transaction was executed in multiple trades at prices ranging from $255.51 to $256.095; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Apple, or a security holder of Apple.
• F7: This award was granted on September 26, 2021. 22,689 RSUs subject to the award vested on April 1, 2024, and 22,688 RSUs vested on each of April 1, 2025 and April 1, 2026.
• F8: This award was granted on September 25, 2022. 22,159 RSUs subject to the award vested on each of April 1, 2025 and April 1, 2026, and 22,159 RSUs are scheduled to vest on April 1, 2027, subject to the terms and conditions of the underlying award agreement.
• F9: This award was granted on October 1, 2023. 19,470 RSUs subject to the award vested on April 1, 2026, and 19,469 RSUs are scheduled to vest on each of April 1, 2027 and April 1, 2028, subject to the terms and conditions of the underlying award agreement.